Allogene (NASDAQ: ALLO) EVP sells 26,269 shares for tax withholding

Q: What insider transaction did Allogene Therapeutics (ALLO) disclose in this Form 4?

The Form 4 reports that EVP of R&D Zachary Roberts sold 26,269 shares of Allogene common stock on January 21, 2026 at a price of $1.56 per share .

Q: Why did Allogene Therapeutics (ALLO) EVP of R&D Zachary Roberts sell shares?

The filing states the 26,269 shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, under a mandated “sell to cover” election in Allogene’s equity incentive plan, and do not represent a discretionary trade.

Q: How many Allogene (ALLO) shares does Zachary Roberts own after the reported sale?

After the transaction, Zachary Roberts beneficially owned 616,866 shares of Allogene common stock in direct ownership.

Q: What was the price per share in the Allogene (ALLO) insider sale on January 21, 2026?

The reported sale price was $1.56 per share for the 26,269 Allogene common shares sold by Zachary Roberts.

Q: Is the Allogene (ALLO) EVP’s Form 4 sale considered a discretionary trade?

No. The footnote explains that the sale was mandated by Allogene’s equity incentive plan as a “sell to cover” transaction for tax withholding and does not represent a discretionary trade by Zachary Roberts.

Q: What is the role of the insider involved in this Allogene (ALLO) Form 4 filing?

The reporting person, Zachary Roberts , is identified as an officer of Allogene Therapeutics, serving as EVP of R&D .

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. reported an insider transaction by EVP of R&D Zachary RobertsJanuary 21, 2026, Roberts sold 26,269 shares of Allogene common stock at $1.56 per share. According to the filing, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, under a mandated “sell to cover” election in the company’s equity incentive plan, and are not a discretionary trade by Roberts.

Following this transaction, Roberts beneficially owned 616,866 shares of Allogene common stock in direct ownership.

Positive

None.

Negative

None.

Insider Trade Summary

Net Seller: 26,269 shares ($40,980)

Net Sell 1 txn

Insider Roberts Zachary

Role EVP of R&D

Sold 26,269 shs ($41K)

Type Security Shares Price Value

Sale Common Stock 26,269 $1.56 $41K

Holdings After Transaction: Common Stock — 616,866 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

01/23/2026 - 04:15 PM

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*
Roberts Zachary

(Last) (First) (Middle)

210 EAST GRAND AVE

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director 10% Owner

X Officer (give title below) Other (specify below)

EVP of R&D

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V Amount (A) or (D) Price

Common Stock 01/21/2026 S 26,269⁽¹⁾ D $1.56 616,866 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Remarks:

/s/Earl Douglas, Attorney-in-Fact 01/23/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Allogene Therapeutics (ALLO) disclose in this Form 4?

The Form 4 reports that EVP of R&D Zachary Roberts sold 26,269 shares of Allogene common stock on January 21, 2026 at a price of $1.56 per share.

Why did Allogene Therapeutics (ALLO) EVP of R&D Zachary Roberts sell shares?

The filing states the 26,269 shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, under a mandated “sell to cover” election in Allogene’s equity incentive plan, and do not represent a discretionary trade.

How many Allogene (ALLO) shares does Zachary Roberts own after the reported sale?

After the transaction, Zachary Roberts beneficially owned 616,866 shares of Allogene common stock in direct ownership.

What was the price per share in the Allogene (ALLO) insider sale on January 21, 2026?

The reported sale price was $1.56 per share for the 26,269 Allogene common shares sold by Zachary Roberts.

Is the Allogene (ALLO) EVP’s Form 4 sale considered a discretionary trade?

No. The footnote explains that the sale was mandated by Allogene’s equity incentive plan as a “sell to cover” transaction for tax withholding and does not represent a discretionary trade by Zachary Roberts.

What is the role of the insider involved in this Allogene (ALLO) Form 4 filing?

The reporting person, Zachary Roberts, is identified as an officer of Allogene Therapeutics, serving as EVP of R&D.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/21/2026		S		26,269⁽¹⁾	D	$1.56	616,866	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

	/s/Earl Douglas, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.